visuel_vexim.jpg

VEXIM: Continued Sales Growth in Q1 2017

Posted On April 19, 2017 By OrthoSpineNews In Financial /  

April 19, 2017

TOULOUSE, France–(BUSINESS WIRE)–Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated Q1 sales results as of March 31st, 2017.

« VEXIM sales performance in Q1 is in line with our expectations. VEXIM continues to gain market share in Europe and Internationally with a market growing around 5%. Our German business is also progressing and we remain confident to reach at least €5 million of sales there and rank among the top 3 market leaders. We maintain our guidance of 30% to 35% growth of sales and aim at reaching profitability for the full year 2017 », said Vincent Gardès, CEO of VEXIM.

Continued growth in the first quarter 2017

Revenue (€ in million – IFRS, as of March, 31st)

Quarterly sales
Q1 2017 Q1 2016 Variation (%)
4.703 3.954 +19%

€4.7 million in sales, VEXIM continues to expand in all geographies

In Europe, Vexim’s business continues to grow and the SpineJack® is becoming progressively the standard of care for vertebral fractures. In France, its domestic market, Vexim continues to grow and increase its market shares. In Germany, the biggest market in Europe (worth €70 million per year), Vexim increased the size of its salesforce to meet the growing demand of the market, for its products. With the addition of Masterflow Plus, Vexim’s secondary product specifically designed for the German market and to address a large potential of patients suffering from osteoporotic compression fractures, Vexim also gained access to Clinicpartners, Agaplesion, AGKAMed and Paul Gerhard Diakonie, counting for 250+ clinics for Vexim to sell into. Vexim will furthermore initiate a clinical study in Germany where the Spinejack® will be more evidence based towards a wider range of indications to follow. In Germany, Vexim is then pursuing the objective of achieving €5.0 million of sales in 2017, and ranking among the top 3 market leaders in the country.

Italy will see Vexim grow to achieve a 20% market share position. With the approval by Sanitas in Spain, one of the largest insurance companies, Vexim expects to see a major step forward in its market expansion in 2017.

Outside of Europe, where sales in Q1 increased by 114% vs Q1 2016, Vexim continues to see growing interest in the SpineJack® technology. As previously announced, Vexim is in the process of launching Spinejack® products in Brazil, Australia and South Korea in the coming months.

Since its launch in 2011, the Spinejack® has now been implanted to more than 46 000 patients which is close to 22 000 surgeries.

Confirmation of 2017 guidance

First quarter 2017 revenues are in line with Vexim’s expectations. The group confirms his guidance for full year 2017 :

  • Sales growth of +30% to +35% (organic)
  • Positive operating and net income, throughout the full year
  • Sales of €5M Sales in Germany and rank among top 3 market leaders

Financial reporting schedule:
2nd quarter sales: July 11th, 20171

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital2, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 66 members on its staff. VEXIM has been listed on NYSE Alternext Paris since May 3rd 2012. For further information, please visit www.vexim.com

SpineJack®3, an innovative implant for treating Vertebral Compression Fractures
The SpineJack® is designed to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by minimally invasive surgery, guided by X-ray, in approximately 30 minutes, which is intended to enable the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

1 Indicative date, subject to changes.
2 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
3 This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.

Nom : VEXIM

Code ISIN : FR0011072602

Code mnémonique : ALVXM

Contacts

VEXIM
Vincent Gardès, CEO
José Da Gloria, Chief Financial Officer
Tel.: +33 5 61 48 48 38
investisseur@vexim.com
or
PRESS RELATIONS
ALIZE RP
Caroline Carmagnol / Wendy Rigal
Tel.: +33 1 44 54 36 66
Tel.: +33 6 48 82 18 94
vexim@alizerp.com

Read More
da_vinci_surgical_not_properly_tested.jpg

Shares of this surgical robot maker just jumped to an all-time high on better-than-expected earnings

Posted On April 19, 2017 By OrthoSpineNews In Financial, Robotics /  

By:  |

Shares of Intuitive Surgical hit an all-time high Wednesday morning after the maker of the da Vinci surgery robot reported first-quarter earnings and sales that beat Street estimates.

The California-based company said it had earnings per share of $5.09 on sales of $674 million for the quarter, topping Thomson Reuters estimates for $4.93 on revenue of $669.7 million.

Important to Wall Street, Intuitive Surgical said Tuesday that it shipped 133 of its da Vinci surgical systems in the first quarter of 2017, compared with 110 robots delivered in the same period one year ago.

The stock traded up more than 7 percent, peaking at $811.89 per share Wednesday, and was on track for its best day since July 2015 when shares gained near 9 percent. Intuitive Surgical’s shares reached a low of $6 back in 2001.

 

READ THE REST HERE

 

Read More
1-2.jpeg

ulrich medical USA® Triples U.S. Spine Business

Posted On April 18, 2017 By OrthoSpineNews In Financial, Spine /  

ST. LOUIS, April 18, 2017 /PRNewswire/ — ulrich medical USA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, today reported full year 2016 financial results with a 15% top line revenue increase for the year ending December 31, 2016 and a 20% growth in EBITDA for the same period.

“In 2010, we announced that we were changing our commercial structure and diversifying our U.S. spine trauma business by entering the degenerative spine market segment. Since that time, we have tripled our revenue, added eleven new FDA-cleared implants to our product portfolio, and we have increased our annual U.S. case numbers by 247%,” said Erika Laskey, Chief Commercial Officer, ulrich medical USA. “Over 50% of our revenue is now done outside of the corpectomy space and we have also just delivered six consecutive years of explosive growth with a 6-year 18% revenue CAGR and 26% EBITDA CAGR.”

“We are extremely proud of our performance in the U.S. market and we are exceptionally grateful to our customers for their support,” said Hans Stover, President and Chief Executive Officer, ulrich medical USA. “As we continue to thrive in our 105th year as a privately held, family-owned and operated company, we are well positioned to continue to bring our technically-advanced products to the market for the benefit of both patients and surgeons who prefer best-in-class spinal implant technologies.”

For more information, please visit www.ulrichmedicalusa.com.

About ulrich medical USA, Inc.

ulrich medical USA, Inc. is a subsidiary of ulrich medical®, an innovative medical technology company headquartered in Ulm, Germany.

Company Contact: e.laskey@ulrichmedicalusa.com

 

SOURCE ulrich medical USA, Inc.

(PRNewsfoto/ulrich medical USA, Inc.)…

Related Links

http://www.ulrichmedicalusa.com

Read More
AAEAAQAAAAAAAAvIAAAAJDliMTc3YjM0LTI2ZDAtNGU4OC04ZDkxLTUzMjVmMGUxYWU1Mg.jpg

Extremity Reconstruction Market : New Business Opportunities & Investment Research Report 2017 – 2025

Posted On April 18, 2017 By OrthoSpineNews In Extremities, Financial /  
04-18-2017 – Health & Medicine, Press release from: TMR Research

The global market for extremity reconstruction is expected to witness a high level of growth in the next few years. The rising number of cases of abnormalities and injuries in the lower and upper extremity of the human body is one of the vital factors estimated to encourage the growth of the global market in the coming years. In addition, several advancements in the healthcare infrastructure are anticipated to accelerate the development of the market in the near future. The implant devices for different parts of the human body comprises the extremity reconstruction market in the coming years.

A tremendous rise in the geriatric population and the rising incidences of obesity and diabetes are some of the major factors that are estimated to fuel the development of the global extremity reconstruction market in the near future. Moreover, the increasing cases of osteoarthritis and rheumatoid are likely to accelerate the growth of the market in the coming years. The rising awareness regarding the benefits of small joint reconstruction implants among patients is predicted to encourage the growth of the global extremity reconstruction market in the next few years.

Request a Brochure of the Report @ www.tmrresearch.com/sample/sample?flag=B&rep_id=1175

Technological advancements and the availability of required infrastructure are projected to augment extremity reconstruction market in North America market in the next few years. The leading players operating in the extremity reconstruction market across the globe are emphasizing on introducing innovative implants in order to attract a large number of consumers and attain a leading position in the market. Additionally, the rising level of competition is predicted to expand the product portfolio and benefit the patients in the coming years.

 

READ THE REST HERE
Read More
09212010_21medtronic_photo2-7714265.jpg

Medtronic sells monitoring, recovery products business for $6.1 billion

Posted On April 18, 2017 By OrthoSpineNews In Financial /  
By Star Tribune – April 18, 2017

Medtronic PLC is selling a large portion of its business in patient monitoring and recovery products to Ohio-based Cardinal Health Inc. for $6.1 billion.

The transaction, which is expected to close in the second quarter of Medtronic’s fiscal year 2018, lets it focus on higher-tech devices like pacemakers and heart defibrillators that have been its historical focus.

Medtronic acquired the medical technology products in its January 2015 merger with Covidien PLC.

The businesses being sold generated approximately $2.4 billion in revenue over the last four reported quarters, Medtronic said. Cardinal Health said the deal would shift 23 product categories and more than 10,000 employees.

“These products — while truly meaningful to patients in need — are best suited under ownership that can provide the investment and focus that these businesses require,” Omar Ishrak, Medtronic’s chief executive, said in a statement. “At the same time, we can put these proceeds to work, investing over the long-term in higher returning internal and external opportunities.”

Based in Ireland, Medtronic has its operational headquarters in Fridley and has large businesses selling heart devices, insulin pumps and products used in spine surgeries.

With headquarters in Dublin, Ohio, Cardinal Health sells a variety of medical products to hospitals, health systems and other clinical entities worldwide.

READ THE REST HERE

Read More

Implanet Announces Q1 2017 Revenue

Posted On April 18, 2017 By OrthoSpineNews In Financial /  

April 18, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:IMPL) (OTCQX:IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces its revenue for the first quarter of 2017.

In € thousands – IFRS* Q1 2017 Q1 2016 Change
Spine (JAZZ) 1,066 837 +27%
Knee + Arthroscopy 982 1,151 -15%
Total revenue 2,048 1,988 +3%

*Unaudited data

In Q1 2017, Implanet recorded a +3% increase in revenue to €2,048 thousand (versus €1,988 thousand in Q1 2016). Jazz® activity increased by +27% to €1,066 thousand (vs. €837 thousand) and accounted for 52% of total revenue (vs. 42%), offsetting the 15% decrease in Knee sales to €982 thousand (vs. €1,151 thousand) because of difficulties in Brazil.

In France, the United States and the rest of the world, Jazz® sales grew by +61% to €417 thousand, +3% to €415 thousand and +34% to €234 thousand respectively. In markets where the Company operates directly, the high-potential degenerative bone disorder segment (adult treatment) saw sales increase by +60% to €353 thousand, accounting for 42% of Jazz® sales (vs. 36% in Q1 2016). Implanet sold 2,032 Jazz® implants over the quarter (vs. 1,197), a 70% volume growth.

Ludovic Lastennet, CEO of Implanet, says:

“Our overall quarterly growth, whilst penalized by the decrease in Knee exports, shows a continuous improvement in Jazz® in terms of both its adoption by surgeons and its share of the Company’s product mix. We have laid the foundation of our current growth by intensifying our efforts regarding the recognition of the clinical value of JAZZ® and the comprehensive nature of our product range. Lastly, we have treated almost 4,000 patients and with more than 20,000 Jazz® implants since its launch. For 2017, we remain confident in our ability to sustain continued growth in Jazz® revenue and establish it as a benchmark in spine surgery. Regarding the Knee segment, we expect activity to stabilize during the second quarter of 2017.”

Next financial press release: Q2 2017 revenue, on July 18, 2017

Annual general meeting: the combined general meeting of Implanet will be held on May 5, 2017 at 10:00 AM CET at the Company headquarters: Technopole Bordeaux Montesquieu, Allée François Magendie, 33650 Martillac, France.
You are invited to participate in the voting of the resolutions. For further information, please send your contact details to: implanet@newcap.eu

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

Disclaimer
This press release contains forward-looking statements concerning Implanet and its activities. Such forward looking statements are based on assumptions that Implanet considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Implanet registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on April 26, 2016 under number R.16-035 and available on the Company’s website (www.implanet-invest.com), and to the development of economic situation, financial markets, and the markets in which Implanet operates. The forward-looking statements contained in this release are also subject to risks unknown to Implanet or that Implanet does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Implanet that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements.

This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for Implanet shares in any country.

Contacts

IMPLANET
Ludovic Lastennet, Tel. : +33 (0)5 57 99 55 55
CEO
investors@implanet.com
or
NewCap
Investor Relations
Florent Alba, Tel. : +33 (0)1 44 71 94 94
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau, Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen, Tel.: +1 917 385 21 60
implanet@alphabronze.net

Read More
blue-cross-blue-shield-hq-minnesota-770-1.jpg

Blue Cross and Blue Shield of Minnesota Announces New “Future Of Health Care” Initiative

Posted On April 17, 2017 By OrthoSpineNews In Financial /  

EAGAN, Minn., April 17, 2017 /PRNewswire-USNewswire/ — Blue Cross and Blue Shield of Minnesota (Blue Cross) announced a new strategic “Future of Health Care” initiative today aimed at addressing health care cost challenges in Minnesota and beyond.  With three strategic pillars, the initiative looks to spur innovation and engagement around new approaches to help build a more stable and sustainable health care market for Blue Cross members and Minnesotans statewide.

“Health care is at a crossroads,” said Michael Guyette, president and CEO of Blue Cross and Blue Shield of Minnesota, announcing the new initiative. “Costs continue to rise, and the premium dollars coming in just aren’t covering the dollars going out in payments to hospitals, physicians, and drug companies.  Our members are stretched.  Our employer partners are stretched.  We need new ideas and approaches that can help members, employers and providers move forward together.

“Blue Cross is the leading health plan in Minnesota.  We can’t wait for someone else to step up.  We need to lead – and that’s what our Future of Health Care initiative is about.  We’re going to innovate to make the health care market more stable and sustainable for everyone, and this is how we are moving forward.”

Earlier this month, Blue Cross reported rising health care costs had pushed the state’s largest health care plan to record operating losses in 2016.  With a negative operating margin, the state’s largest non-profit health plan said it had been necessary to dip deeply into reserves to cover costs, despite 2016 premium increases in most segments.

In Minnesota’s individual market segment, Blue Cross said it had absorbed unsustainably large losses, in addition to major cost pressures in public programs and heavy utilization by Minnesotans covered under the state’s Medicaid program.

The losses reported by Blue Cross were not unique.  Most of Minnesota’s health plans reported dismal 2016 financial performance.  Medicaid losses are a particular problem, with costs reaching critical levels.  There’s already been significant disruption and instability for Medicaid program enrollees.

“Minnesota health care costs are a flashing red light,” Guyette said.  “It’s not sustainable.”

“We need to innovate,” he said.  “Blue Cross has served Minnesotans for more than 80 years. We have nearly 3 million members looking to us for leadership.”

The Future of Health Care initiative has three strategic pillars – Clinical Innovation, Care Management, and Network and Payment – with specific initiatives under each:

  • The Clinical Innovation pillar will help members better navigate the care system and address their specific health care needs in the best way possible through collaborative partnerships.
    For example, the Mayo Clinic Living Donor Kidney Program leverages Mayo’s expertise and innovative treatment for complex medical conditions.  Blue Cross worked with Mayo Clinic to create a new program, launched recently by a handful of Minnesota employers, to match potential donors willing to help someone by donating a kidney, but who may not be compatible with that relative or friend.  The program creates a “donor chain,” matching people to donate a kidney to someone they didn’t know, while someone else donates an organ to their friend or relative. Already, a “paired donation” type program is being used in 20 percent of Mayo’s kidney transplant cases.  The result is better clinical outcomes and lower costs for Blue Cross members.  Blue Cross is also starting to guide members in need of specific orthopedic procedures and those who have low back pain to high value providers.
    Other new initiatives include a new consumer-centric diabetes solution, designed in collaboration with the American Diabetes Association that features new digital tools, peer support, care coordination and value-based incentives.  A new Maternity Management pilot for Blue Cross Medicaid members features early member engagement and enhanced support for new mothers-to-be.  The pilot is community-based and leverages community and provider partners, including county-based public agencies, to better support women and their babies at this most important time.
  • Advancing Care Management, Blue Cross says it will leverage a broad range of tools to help its members’ receive better coordinated and evidence-based care, everything from basic health coaching and utilization management to care advocacy, specialty-care coordination and care transition support.  The company said it will continue its emphasis on high-complexity care, leveraging dedicated managers and health coaches, while also creating a new “inter-disciplinary care rounds” approach, in which cross-functional clinical teams identify holistic approaches on behalf of members.
  • In the Network and Payment pillar, the plan will focus on identifying and leveraging high value networks considering provider cost, efficiency and quality, both statewide and regionally.  Building on advances and innovations in this area, Blue Cross is already working to incorporate aligned incentive contracts, patient-centered medical homes, bundled payments for key procedures, value-based contracts for Medicaid member providers, and new insurance programs leveraging Accountable Care Organizations (physicians, clinics and hospitals) capable of delivering high-value care to members.
    Through payment reform, Blue Cross wants to lower the cost of care and achieve better predictability in employer and member out-of-pocket costs by establishing a care model where it pays for value, not volume, shifting to a system that rewards quality and affordability.
    The results of an effective care system that prioritizes value are fewer inpatient hospitalizations, lower readmission rates, higher quality care, and more appropriate use of services when compared to volume-based care.

“We’re already innovating to advance our Future of Health Care pillars,” said Guyette, “but we’re also going to partner with our providers, employers and members on new ideas and new approaches.  We’ll need everyone working together if these cost challenges are to be met.”

About Blue Cross and Blue Shield of Minnesota
Blue Cross and Blue Shield of Minnesota, with headquarters in the St. Paul suburb of Eagan, was chartered in 1933 as Minnesota’s first health plan and continues to carry out its charter mission today: to promote a wider, more economical and timely availability of health services for the people of Minnesota. A nonprofit, taxable organization, Blue Cross is the largest health plan based in Minnesota, covering 2.9 million members in Minnesota and nationally through its health plans or plans administered by its affiliated companies. Blue Cross and Blue Shield of Minnesota is an independent licensee of the Blue Cross and Blue Shield Association, headquartered in Chicago. Go to bluecrossmn.com to learn more.

 

SOURCE Blue Cross and Blue Shield of Minnesota

Related Links

http://www.bluecrossmn.com

Read More
4w.png

4WEB Medical Announces Record Growth in Q1 of 2017

Posted On April 17, 2017 By OrthoSpineNews In Financial /  

BOCA RATON, Fla., April 13, 2017 /PRNewswire/ — 4WEB Medical, the industry leader in 3D printed implant technology, announced today at the annual meeting of the International Society for the Advancement of Spine Surgery (ISASS) that the company achieved its largest revenue quarter to date in the first quarter of 2017.  “The mark of a truly successful orthopedic implant company is sustained quarter over quarter growth, irrespective of market seasonality or other external factors,” said Geoffrey Bigos, Vice President of Spine Sales at 4WEB Medical. “Our continued success and rapid expansion is a testament to our surgeon customers belief in the difference that 4WEB’s Truss Implant Technology makes on surgical outcomes for their patients.”

4WEB’s record breaking quarter was highlighted by strong demand for its comprehensive Posterior Spine Truss System product line for TLIF procedures. The company also expanded sales and distribution into dozens of new hospitals during the quarter, making significant investments in sales infrastructure to further its reach into new markets. The first planned U.S. surgeries with the company’s new Lateral Spine Truss System in Q2 are certain to further advance its market leading position.

“The proliferation of 3D printed titanium implants across the industry has fueled the market adoption of these devices in spine surgery,” said Jim Bruty, 4WEB’s Senior Vice President of Sales and Marketing. “4WEB’s distinct advantages over competitive 3D printed and other titanium implants are clear; increased bone implant surface interface, more volume for bone through-growth, and transference of load throughout the implant to create a mechanical environment for biological fusion to occur.”

4WEB Medical is an implant device company founded in 2008 in Dallas, Texas. Thirty years of research in topological dimension theory led to the discovery of a novel geometry, the 4WEB, that can be used as a building block to create high-strength, lightweight web structures. The company leveraged this breakthrough along with cutting-edge 3D printing technology to develop 4WEB Medical’s proprietary truss implant platform. The 4WEB Medical product portfolio includes the Cervical Spine Truss System, the Anterior Spine Truss System, the Posterior Spine Truss System, the Lateral Spine Truss System, and the Osteotomy Truss System. 4WEB is actively developing truss implant designs for knee, hip, trauma and patient specific orthopedic procedures.

For more information about 4WEB Medical, 4WEB’s Truss Implant Technology, and the Spine Truss Systems, please visit www.4WEBMedical.com.

SOURCE 4WEB Medical

Related Links

http://www.4webmedical.com

Read More
rea-medicrea-5a4276cf1b952a23a2381b1b66a95324546377b474c62e264272afb9a3c02711.jpg

Medicrea Releases First Quarter Sales For 2017

Posted On April 17, 2017 By OrthoSpineNews In Financial /  

April 13, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The Medicrea Group (Alternext Paris: FR0004178572 – ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, publishes its sales for the 1st quarter of 2017.

(€ millions) 2016 2017 Variation
1st Quarter 7.0 7.0 –
Changes in exchange rates had no material impact on year to year comparison

During the 1st quarter of 2017, Medicrea continued the major corporate restructuring initiated in 2016 with the permanent closure of the original La Rochelle site and the relocation of all manufacturing operations to the new ultra-modern facility in Rillieux-la-Pape, near Lyon. The Company is now well positioned to respond to new market opportunities.

This transfer involved a large part of the Company’s resources, which were also heavily involved in two successful certification audits conducted by the FDA (Food and Drug Administration) for the marketing of implants in the United States and by LNE/G-MED (Working Group for the Evaluation of Medical Devices) for renewal of the CE marking.

Against this backdrop, Q1 sales remained stable compared to the same period of the previous year at €7 million.

Adoption of the Company’s UNiD™ technology continued over Q1 2017 with a 38% increase in surgeries utilizing patient-specific UNiD™ Rods in the United States compared to the same quarter of 2016.

Events: ISASS 2017

Medicrea will be showcasing UNiD™ Adaptive Spine Intelligence and patient-specific implants this week at Booth #420 of the 17th Annual Conference of The International Society for the Advancement of Spine Surgery (ISASS) held in Boca Raton, Florida from April 12 to 14, 2017. On Thursday, April 13th, Medicrea technology, including early clinical results with UNiD™ 3D-printed patient-specific vertebra, features twice in the conference’s official scientific program in Presentation 483 and Presentation 456. More information on the event is available here.

Next publication: Sales for the 1st half of 2017: July 11, 2017, after market.

About Medicrea (www.medicrea.com)

Medicrea specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, Medicrea leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, Medicrea is an SME with 160 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, Medicrea is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit: www.medicrea.com

Connect with Medicrea:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

Medicrea is listed on
ALTERNEXT Paris ISIN: FR 0004178572– Ticker: ALMED

Contacts

Medicrea
Denys SOURNAC
Founder, Chairman and CEO
dsournac@medicrea.com
or
Fabrice KILFIGER
Chief Financial Officer
fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87
or
Media
Russell WARD for Medicrea
russell@theconfluencegroup.com
Tel: +1 310 424 8356

Read More
index.6jpg-lightbox.jpg

EOS Imaging Reports 34% Revenue Growth for the First Quarter of 2017

Posted On April 13, 2017 By OrthoSpineNews In Financial /  

April 12, 2017

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible for PEA-PME savings schemes in France), the pioneer in 2D/3D orthopaedic medical imaging, today announced its consolidated revenue for the first quarter ended March 31, 2017.

Marie Meynadier, Chief Executive Officer of EOS imaging, said, “We delivered a quarter of strong growth, building on our positive momentum in EMEA, including a first sale in Israel and significant sales in the United Kingdom. This also reflects an excellent momentum in the Asia-Pacific region, driven by market approval in China obtained in 2016.”

€ millions Q1 2017 Q1 2016
Equipment sales 5.47 4.09
As a % of total revenues 77% 77%
Sales of maintenance 1.40 0.99
As a % of total revenues 19% 18%
Sales of consumables and services 0.26 0.24
As a % of total revenues 4% 5%
Total revenues 7.13 5.33
Unaudited data
  • First-quarter 2017 revenue up 34% to €7.13 million

The Company sold 14 EOS® platforms in the first quarter of 2017, compared to 10 in the same period last year. Revenues from sales of equipment totalled €5.47 million, an increase of 34%.

Sales of maintenance contracts increased by 41% to €1.40 million against €0.99 million in the first quarter of 2015. This reflects the continued increase in the installed base of EOS systems and an associated high contract subscription rate after warranty.

Sales of consumables and services were €0.26 million in the first quarter of 2017 versus €.024 million in the first quarter of 2016.

  • The strong growth in sales was driven by continued expansion in EMEA and Asia-Pacific
€ millions Q1 2017 Q1 2016
EMEA 3.21 2.45
North America 2.48 2.85
Asia-Pacific 1.44 0.03
Total revenues 7.13 5.33
Unaudited data

EOS reported continued sales momentum in EMEA, generating revenue of €3.21 million, an increase of 31% compared to the same period last year. This included strong sales in the United Kingdom as well as a first sale in Israel.

Sales in North America were €2.48 million, a decrease of 13% compared to the first quarter of 2016, which included particularly high sales in this region.

Sales in the Asia-Pacific region were €1.44 million. This largely reflects sales in China following regulatory approval in 2016.

  • Chief Financial Officer Transition

Anne Renevot, EOS imaging’s Chief Financial Officer, will leave the Company at the end of April to pursue other professional interests. The EOS imaging financial team, composed of 5 employees, will be led by an interim-CFO until the recruitment of a permanent CFO is completed. “I would like to thank Anne for her professionalism, commitment and contribution to the development of the Company. I wish her as much success in her new career as she had in our collaboration,” said Marie Meynadier.

For more information, please visit www.eos-imaging.com.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

About EOS imaging

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system dedicated to osteoarticular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.

Next press release: 2017 First-half sales on July 18, 2017 (after the market close)

Contacts

EOS imaging
Anne Renevot, +33 (0)1 55 25 61 24
CFO
investors@eos-imaging.com
or
NewCap
Financial communication and investor relations
Pierre Laurent / Valentine Brouchot
+33 (0)1 44 71 94 96
eosimaging@newcap.eu
or
The Ruth Group (US)
Press relations
Joanna Zimmerman, 646-536-7006
jzimmerman@theruthgroup.com

Read More